Acute appendicitis complicated by ovarian vein thrombosis

Abstract

Ovarian vein thrombosis (OVT) is a rare cause of acute abdominal pain and is mainly related to pregnancy and affects approximately 1 in every 2,000 deliveries and abortions. However, this diagnosis should be considered not only in postpartum patients but also in women with pelvic inflammatory disease (PID), malignancy, women who have recent abdominal surgery and who have a known hypercoagulable state. Anticoagulation and antibiotics are the mainstays of treatment for OVT. Complications of OVT include sepsis, the extension of the thrombus to the inferior vena cava and renal veins, and pulmonary embolism. The incidence of pulmonary embolism is reported to be 13.2% and represents the main cause of mortality due to OVT. We report a case of 40-years old female patient presenting with OVT, which was accompanied by acute appendicitis. In this woman, OVT was not related to pregnancy. The patient underwent an appendectomy, which proved positive on histopathology result. Patient symptoms improved after appendectomy with antibiotics and anticoagulation therapy. A month later, a follow-up computed tomography (CT) scan of the abdomen revealed a complete resolution of OVT. OVT, though a rare presentation, should be included in the differential diagnosis for women presenting with acute abdomen. Proper diagnosis and timely management can prevent catastrophic complications. Our case thus highlights the importance of considering the rare diagnosis of OVT with acute appendicitis.

Bioequivalence Study of Two Formulations of Simvastatin 20 mg Tablet in Healthy Filipino Participants under Fasting Conditions: A Randomized, Open-label, Two-way Crossover Study

“…This could lead to lowering the risk of total mortality by reducing coronary heart disease (CHD) deaths, non-fatal myocardial infarction and stroke, and the need for revascularization procedures in patients at high risk of coronary events. 4,6,7…”

“…It is an oral hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor indicated to help lower cholesterol production and reduce dyslipidemia-associated complications. 4 The drug inhibits the first and rate-limiting step in cholesterol biosynthesis. 4,5 It is available in 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg tablets.…”

“…4 The drug inhibits the first and rate-limiting step in cholesterol biosynthesis. 4,5 It is available in 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg tablets. The maximum recommended dose is 40 mg/day.…”

“…The maximum recommended dose is 40 mg/day. 4,6 It is well-absorbed from the gastrointestinal tract (maximum concentration at 1.3-2.4 h) with low bioavailability (5%) due to first-pass metabolism. It is excreted via the feces (60%) and urine (13%).…”

“…7 Common adverse effects include headache, myalgia, abdominal pain, constipation, nausea, and upper respiratory infections. 4,6 Locally, simvastatin products are of different brands and prices, with the generics costing around 23 -43% of the innovator, 8 illustrating that bioequivalent generics could yield significant savings for patients.…”